Main content
New Product Development Feature
CSL develops new protein-based medicines to save lives by preventing or treating serious medical conditions.
Our Core Capabilities
Our core capabilities are in products derived from human plasma, vaccines, recombinant biotechnology and our proprietary ISCOMATRIX® adjuvant.
CSL is a global leader in the development and manufacture of therapeutic products derived from human plasma. We have established international markets for our influenza vaccines. ISCOMATRIX® adjuvant may be used to enhance influenza vaccine effectiveness and in the development of new vaccines both by CSL and major vaccine manufacturers through license and option agreements. CSL uses its expertise in recombinant proteins, particularly monoclonal antibodies, in research programs on cancer, inflammation and immunology.
We maintain strong long-standing strategic partnerships with academic institutions and corporations in Australia, North America and Europe. These collaborative partnerships support a range of effective research programs, including both basic and applied research in plasma products, vaccines and recombinant biotechnology.
CSL's team of scientists in the Molecular Science and Biotechnology Institute at Melbourne University (Bio21) focuses on research into recombinant protein-based medicines and works closely with Australian and global research and development colleagues. Shown here are Bio21 scientists, Therese Lynch (above), Anne McDonald (below left) and Anabel Silva.
